Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IMA203 Product · 1 trial · 4 indications
Number of patients with dose-limiting toxicities (DLTs)
Treatment emergent adverse events (TEAEs), Adverse events of special interest (AESIs) and Treatment-emergent serious adverse events (TESAEs).
Objective response rate (ORR) based on best overall response (BOR) of complete response (CR) and partial response (PR) centrally assessed (by a BICR1) using RECIST1.1
| Arm | Type | Description |
|---|---|---|
| Dose Escalation A (closed to enrollment) | EXPERIMENTAL | Dose escalation of IMA203 |
| Extension Cohort A | EXPERIMENTAL | IMA203 at RP2D |
| Extension Cohort B (closed to enrollment) | EXPERIMENTAL | IMA203 at RP2D + nivolumab |
| Extension Cohort AA | EXPERIMENTAL | IMA203 at final RP2D (flat dose) |
| Uveal Melanoma | EXPERIMENTAL | IMA203 at RP2D |
| Dose Escalation B | EXPERIMENTAL | Dose escalation of IMA203CD8 |
| Extension Cohort C | EXPERIMENTAL | IMA203CD8 at dose levels confirmed to be safe |
| Extension Cohort D | EXPERIMENTAL | IMA203CD8 at dose levels confirmed to be safe; without IL-2 |
| Ovarian | EXPERIMENTAL | IMA203CD8 monotherapy at dose levels confirmed to be safe |
| Endometrial | EXPERIMENTAL | IMA203CD8 monotherapy at dose levels confirmed to be safe |
| Head and Neck, Lung, and Triple Negative Breast Cancer | EXPERIMENTAL | IMA203CD8 monotherapy at dose levels confirmed to be safe |
| Rare Cancers | EXPERIMENTAL | IMA203CD8 monotherapy at dose levels confirmed to be safe |
| Name | Type | Description |
|---|---|---|
| IMA203 Product | BIOLOGICAL | The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula |
| IMA203 product- flat dose | BIOLOGICAL | The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells |
| IMA203CD8 Product | BIOLOGICAL | The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula |
| Nivolumab | DRUG | Nivolumab will be given post IMA203/IMA203CD8 infusion, after hematologic recovery is achieved. Clinical supply provided by Bristol Myers Squibb. |
| IMADetect® | DEVICE | IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in Immatics clinical trials. |
Inclusion Criteria: * Patients must have recurrent/progressing and/or refractory solid tumors and must have received or not be eligible for all available indicated standard of care treatment. * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * HLA-A\*02:01 positive * For patients w...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
IMA203 Product is an investigational monoclonal antibody being developed for the treatment of refractory cancer, recurrent cancer, and solid tumors in adults. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
IMA203 Product is being developed by Immatics N.V., a biopharmaceutical company listed on the stock exchange under the ticker symbol IMTX. The company is conducting clinical trials for this investigational therapy in the United States and Germany.
IMA203 Product is currently in Phase 1 clinical development. It is an investigational drug being studied in a clinical trial for refractory and recurrent solid tumors. The drug has not yet been approved for commercial use.
IMA203 Product is being studied in a Phase 1 clinical trial with the identifier NCT03686124. The trial is titled 'ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors' and is currently recruiting participants.
IMA203 Product is a monoclonal antibody, a type of targeted therapy designed to interact with specific proteins involved in cancer. The exact molecular target of IMA203 Product has not been disclosed in available information.